Home World News Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up... World News Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 791 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe... October 4, 2021 A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with... January 29, 2025 Tebentafusp Shows Promising Clinical Activity with an Acceptable Safety Profile in... October 17, 2022 Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients... March 17, 2025 Load more HOT NEWS Improving cancer care for the LGBTQ+ community Welcome to our new committee chairs A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit... A Short-Course of Induction Chemotherapy Followed by Chemoradiotherapy Significantly Improves Survival...
